title: Urology pertinent neuroendocrine tumors: focusing on renal pelvis, bladder, prostate located sympathetic functional paragangliomas.
abstract: Urology pertinent neuroendocrine neoplasias are more and more driving to research attractive contributions mainly as regards the urinary tract paragangliomas, besides the prostate cancer neuroendocrine differentiation. About such visceral sympathetic paragangliomas, a considerable attention is aroused by those concerning the renal pelvis, urinary bladder and, particularly, the prostate gland. Essential catecholamine/adrenergic signal-mediated pathophysiological implications and outlined diagnostic approaches are here taken into consideration. Particularly, to reach an accurate functional diagnostic assessment, both plasma and urine catecholamine level tests are required together with ¹²³I or ¹³¹I-meta-iodobenzylguanidine (MIBG) scan while ¹³¹I-, instead of ¹²³I-, labeled MIBG, proving to be also useful to targeted radionuclide therapy of sympathetic paragangliomas. Nevertheless, a thorough diagnostic confirmation should be obtained by a proper histologic/ immunohistochemical study, so that it respectively highlighting the typical "zellballen" cell setting and neuroendocrine tumor cell specific biomarkers such as chromogranin-A, synaptophysin, neuron-specific enolase. Open/laparoscopic/robot-assisted surgical procedures are performed under α1 (doxazosin, prazosin) - and β(propranolol)-adrenergic blockade to avoid the risk of an intraoperative adrenergic signal-triggered hypertensive crisis, what moreover may occur also during cystoscopy and biopsy in case of bladder or prostate paraganglioma. Given a conceivable likeness, about some adrenergic-mediated pathophysiological implications, between prostate paraganglioma and prostate cancer neuroendocrine transdifferentiation - although as regards two obviously different diseases - a reliable pathogenetic matter concerning prostate paraganglioma is requiring novel research approaches.
authors.forename: C
authors.initials: C
authors.lastname: Alberti
mesh_terms: D015415:Biomarkers / Q000097:blood / Q000652:urine; D002395:Catecholamines / Q000097:blood / Q000652:urine; D053379:Chromogranin A / Q000097:blood / Q000652:urine; D003937:Diagnosis, Differential; D006801:Humans; D007682:Kidney Pelvis / Q000473:pathology; D008297:Male; D018358:Neuroendocrine Tumors / Q000097:blood / Q000175:diagnosis* / Q000652:urine; D010235:Paraganglioma / Q000175:diagnosis; D010386:Pelvic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000652:urine; D010751:Phosphopyruvate Hydratase / Q000097:blood / Q000652:urine; D011237:Predictive Value of Tests; D011471:Prostatic Neoplasms / Q000175:diagnosis; D012680:Sensitivity and Specificity; D016708:Synaptophysin / Q000097:blood / Q000652:urine; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis; D014572:Urology
chemical_list: D015415:Biomarkers; D002395:Catecholamines; D053379:Chromogranin A; D016708:Synaptophysin; D010751:Phosphopyruvate Hydratase